Julio Marcolini, MD
Infectious Disease · Sun City West, AZNPI 1487647038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 17 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$79
- Medtronic$72
- Abbott$66
- Inspire Medical Systems, Inc.$55
- Merck$53
- Boston Scientific$52
- plus $52 from 3 others
What the payments were for
- Food & beverage$430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $79 |
| Medtronic | 2 | $72 |
| Abbott | 2 | $66 |
| Inspire Medical Systems, Inc. | 2 | $55 |
| Merck | 2 | $53 |
| Boston Scientific | 2 | $52 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Lilly USA, LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $12 |
How this compares
$430 in reported general payments places this provider in the 55th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 20 | $73,725 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $29,417 |
| TivicayDolutegravir Sodium | 13 | $28,014 |
| Voriconazole | 14 | $5,373 |
| Vancomycin Hcl | 43 | $4,447 |
| CeftriaxoneCeftriaxone Sodium | 43 | $4,335 |
| Fluconazole | 48 | $3,428 |
| Cefepime Hcl | 15 | $2,101 |
| Doxycycline Hyclate | 29 | $480 |
| Cephalexin | 36 | $479 |
| Ciprofloxacin Hcl | 22 | $431 |
| Ethambutol Hcl | 11 | $337 |
| Amoxicillin | 39 | $148 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Sun City West
- Victor BadgerSun City West$620
- Thanes VanigPhoenix$258K
- Anita KohliChandler$213K
- Vipul GanatraPhoenix$151K
- Jorge MeraNogales$101K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Edward CachayScottsdale$26K
- Aman DalalScottsdale$22K
- Adriana GaidiciPhoenix$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.